Camp4 Therapeutics Corp(CAMP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,665 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CAMP
Events flagged as statistical outliers against CAMP's own multi-year baseline — not fixed dollar thresholds.
- Insider cluster2026-08-03
5 insiders bought $4,923,857 of CAMP in 30 days — 10.0σ above this company's 2-year norm
View source filing →
CAMP Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Camp4 Therapeutics Corp (CAMP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CAMP at 25.3/100 on a 32-signal composite quality model, placing it at rank #2,665 of 2,962 stocks — the bottom half of the AI-ranked universe. CAMP scores in the top quartile across revenue growth (98.2). Areas of concern include balance sheet strength (0.6) and revenue scale (1.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Camp4 Therapeutics Corp reports quarterly revenue of $1.8M, net income of $-33.5M, free cash flow of $-12.8M. Top institutional holders of CAMP by reported 13-F value include Jupiter Topco, 5AM Venture Management, FMR, based on the most recent SEC filings. CAMP trades on the Nasdaq exchange and files with the SEC under CIK 1736730. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CAMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Camp4 Therapeutics Corp directly from SEC EDGAR. Camp4 Therapeutics Corp's 13F Pro composite quality score has ranged between 13 and 27 since 2026, currently 25.3 — a stable long-term trajectory across 41 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.8M
Net Income
Q2 2026
$-33.5M
Free Cash Flow
Q2 2026
$-12.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+436.5% YoYNet Income
-55.2% YoYOperating Income
+1.0% YoYEPS (Diluted)
+76.0% YoYTotal Assets
+50.4% YoYOp. Cash Flow
+35.1% YoYFree Cash Flow
+35.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $3.5M +436.5% | $652.0K +86.3% | $350.0K | — |
| Net Income | $-80.4M -55.2% | $-51.8M -5.1% | $-49.3M | — |
| Operating Income | $-52.6M +1.0% | $-53.1M -2.3% | $-51.9M | — |
| EPS (Diluted) | $-2.65 +76.0% | $-11.04 -76.9% | $-6.24 | — |
| Total Assets | $117.8M +50.4% | $78.3M +42.5% | $54.9M | — |
| Operating Cash Flow | $-29.6M +35.1% | $-45.6M -3.2% | $-44.2M | — |
| Free Cash Flow | $-29.8M +35.2% | $-46.0M -2.6% | $-44.8M | — |
Get alerted when CAMP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Camp4 Therapeutics Corp including:
Top Institutional Holders of CAMP
Jupiter Topco LLC
$27.6M6,307,636 sh5AM Venture Management, LLC
$25.6M5,869,091 shFMR LLC
$21.4M4,904,339 shVivo Capital, LLC
$18.6M4,246,568 shBALYASNY ASSET MANAGEMENT L.P.
$11.3M2,575,724 sha16z Capital Management, L.L.C.
$9.3M2,125,339 shADAGE CAPITAL PARTNERS GP, L.L.C.
$8.6M1,960,784 shTrails Edge Capital Partners, LP
$8.4M1,932,937 shBlackRock, Inc.
$7.2M1,644,134 shVANGUARD CAPITAL MANAGEMENT LLC
$6.7M1,533,489 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $27.6M | 6,307,636 |
| 5AM Venture Management, LLC | $25.6M | 5,869,091 |
| FMR LLC | $21.4M | 4,904,339 |
| Vivo Capital, LLC | $18.6M | 4,246,568 |
| BALYASNY ASSET MANAGEMENT L.P. | $11.3M | 2,575,724 |
| a16z Capital Management, L.L.C. | $9.3M | 2,125,339 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $8.6M | 1,960,784 |
| Trails Edge Capital Partners, LP | $8.4M | 1,932,937 |
| BlackRock, Inc. | $7.2M | 1,644,134 |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.7M | 1,533,489 |
Companies Similar to CAMP
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
X4 Pharmaceuticals, Inc
Ovid Therapeutics Inc.
Upstream Bio, Inc.
Foghorn Therapeutics Inc.
Syndax Pharmaceuticals Inc
UroGen Pharma Ltd.
Solana Co
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CAMP on your watchlist
Track score changes the day Camp4 Therapeutics Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CAMP a good stock to buy?
13F Pro's AI-powered analysis of Camp4 Therapeutics Corp (CAMP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CAMP are available on the CAMP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CAMP is classified as a small company.
Which hedge funds own CAMP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CAMP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Camp4 Therapeutics Corp's investment landscape.